Menopausal hormone therapy decreases the likelihood of diabetes development in peri‑menopausal individuals with prediabetes
Main finding · Incidence of DMResult — go to the resultHazard ratio 0.693 95 % CI 0.577–0.832Authors' conclusion
In our study, we demonstrate a sustained 20-year decrease in the risk of diabetes among premenopausal individuals with prediabetes who undergo menopausal hormone therapy.
Study context
- Population
- Individuals aged 46–60 with prediabetes prior to menopause
- Participants
- 6,566 individuals
- Exposure
- Menopausal hormone therapy (MHT) vs non-MHT
- Outcome
- Incidence of DM
- Follow-up
- 20-year follow-up
Methodological detailspropensity score matching, TriNetX U.S. Collaborative Network
- Propensity score matching
- TriNetX U.S. Collaborative Network
Main finding
As reported in the abstract
Hazard ratio
0.693
95 % CI 0.577–0.832
MHTvs non-MHT
HR 0.693 (95 % CI 0.577–0.832)
Observational data: associations, not effects.
Further findings
DM incidence by age
- Significant protective effects in individuals aged 46-50 and 55-60
DM incidence by race
- Significant benefit of MHT in White individuals but not in Black or Asian populations
DM incidence by BMI
- Significant risk reduction with MHT with BMI ≤24.9 and 25-29.9 kg/m 2, but not with BMI ≥30 kg/m 2
Original publication
Menopausal hormone therapy decreases the likelihood of diabetes development in peri‑menopausal individuals with prediabetes. Diabetes Metab. Published 5 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →